Sermorelin

II. What is this compound?

Sermorelin acetate is also known as GHRH (1-29). It solves a problem of size. Full-length GHRH is a bigger molecule. Researchers found the key part at the front. The first 29 residues give full activity [3] PMID: 18031173 . GHRH is the hormone that tells the pituitary to act. Build those 29 amino acids by hand (Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2). You get a compound that speaks the pituitary's own language.

Sermorelin was built as a test tool and a study tool. It was meant to test and wake the hypothalamic-pituitary-somatotropic axis. The axis is the chain from brain to pituitary to growth hormone. The peptide binds GHRH receptors on somatotrophs. Somatotrophs are the cells that make growth hormone. The binding sets off inner cell events. New hormone is made. The hormone is released in pulses.

The half-life tells the rest of the origin story. It is about 11–12 minutes in the vein. This matches how fast the body breaks down GHRH. Shots under the skin stretch that window. The receptor stays on for longer in research use. What sets sermorelin apart from direct growth hormone is structure. The peptide does not flood the body with outside hormone. It wakes the body's own production. Research suggests this keeps pituitary reserve. It also keeps more natural pulses [4] PMID: 9141536 .

In the clinic, sermorelin has served two masters. It is used as a test for growth hormone lack (1 mcg/kg in the vein). It is also used as a longer treatment (0.2–0.3 mg under the skin at bedtime). Both use the same core step. That step comes next.

III. How it works

Most growth hormone steps use force. They inject outside growth hormone. High levels are the cost. Sermorelin picks a lock instead. Research suggests this GHRH copy wakes the pituitary [5] PMID: 18031173 . GHRH is the brain's own release signal. The peptide keeps the body's own feedback loops. It keeps natural pulses too.

The path is clear. Sermorelin binds GHRH receptors on somatotrophs. Somatotrophs are the cells that make growth hormone. The bond turns on adenylyl cyclase. cAMP inside the cell rises. cAMP is a small cell messenger. It sets two steps. New growth hormone message RNA is made. Stored growth hormone vesicles are emptied [6] PMID: 18031173 . Growth hormone is the hormone the pituitary makes. The output is a natural release. It is closer to the body's own way than a shot.

Clinical studies indicate that a nightly shot under the skin wakes the axis in minutes. Peak growth hormone comes 30–60 minutes after the shot [7] PMID: 9141536 . That first response stays the same over months. The pituitary does not seem to shut down from steady GHRH use.

The reach goes past growth hormone. The blood level of IGF-I and IGFBP-3 rises in two weeks [8] PMID: 9141536 . IGF-I and IGFBP-3 are markers of anabolic signal. IGFBP-1 stays the same. The mix is not the same as direct growth hormone.

That leaves the core question. Does keeping the body's own feedback give different long-term results than skipping it? The clinical data give some hints.

• Activation of GHRH receptors on pituitary somatotrophs to stimulate endogenous GH secretion
  PMID 18031173
• Preservation of pituitary reserve and GH neuroendocrine axis function
  PMID 9141536
• Stimulation of pituitary gene transcription of hGH messenger RNA
  PMID 18031173

IV. Research Findings

Clinical work gives sermorelin a rare asset: random controlled trials. In one, older adults took a nightly shot. Nightly 12-hour growth hormone levels rose in both men and women [9] PMID: 9141536 . Growth hormone is the hormone the pituitary makes.

Body shape changed too. Over 16 weeks, men gained lean mass. Insulin use got better. Skin got thicker in both groups. Skin thickness marks connective tissue work [10] PMID: 9141536 . These shifts match what a busier growth hormone–IGF-I axis is known to do for protein work and tissue repair.

Kids' data go further. For children with growth hormone lack from no known cause, trials show subcutaneous sermorelin (30 mcg/kg at bedtime) helped growth. Height speed rose and held over 12 months [11] PMID: 18031173 . The gain sat a bit below direct somatropin. Somatropin is lab-made growth hormone. But this route kept pituitary function rather than cutting it. Researchers find that trade worth a look.

Life quality adds color. Older adults felt better in general. Men also saw more drive. Women did not see that change as often [12] PMID: 9141536 . Those group gaps are still a focus of study.

In each study, the same line holds: sermorelin wakes what the body already has. That in-body route may be why results feel more in step with normal life than shots of outside growth hormone. It also shows why the dose lines matter. That is the next read.

• growth-hormone-deficiency clinical
  PMID 18031173
• body-composition clinical
  PMID 9141536
• skin-health clinical
  PMID 9141536
• sleep-quality anecdotal

V. Dosage Context Explained

Sermorelin dose history splits by use, and the split shows how deep the study goes.

For diagnostic growth hormone stimulation tests, the set plan is 1 mcg/kg in the vein [13] PMID: 18031173 . One dose gives a quick, trackable growth hormone rise. It helps check pituitary reserve. Reserve is how much the gland can still give. The test is well held. Peak growth hormone comes in 30–60 minutes.

Study plans for use look different: 0.2–0.3 mg (200–300 mcg) under the skin at bedtime [14] PMID: 9141536 . The clock does real work here. A 2100 h shot lines up with the night's natural growth hormone rise. This may help the body take it in. Trials kept this line for 16 weeks with no big safety flags.

The blood data reward a simple plan. The half-life is short (~11–12 minutes in the vein). Sermorelin does not pile up in tissue. Shots under the skin stretch the useful window. Many shots a day are not the norm. One evening shot works with the body's clock. It does not fight it.

Kids' plans differ again: 30 mcg/kg under the skin at bedtime, set by weight. This was studied to help growth in children who lack growth hormone [15] PMID: 18031173 . Each figure here comes from set clinical studies. Replies vary with starting growth hormone level, age, and body shape. What the same trials saw for side effects is the next read.

• Administration Routes

  subcutaneous

  Range

  0.2–0.3 mg (200–300 mcg) at bedtime

  adult research protocols; diagnostic IV doses differ

  PMID 9141536
• Administration Routes

  intravenous

  Range

  1 mcg/kg bodyweight

  diagnostic GH stimulation test

  PMID 18031173

VI. Side Effects: Research Context

Among peptides, sermorelin's safety file is well lit. It has real clinical trials with checks, not just talk. In test use, the top notes are short face flush and shot site pain [16] PMID: 18031173 . They are mild. They fade on their own.

Longer use studies saw very little. The one clear note was high blood fat in some people. It went back to base by study end [17] PMID: 9141536 . Blood pressure, blood sugar on an empty set, and bone density stayed the same over 16 weeks.

Worries match those for any growth hormone wake-up tool. Active cancer stays a bar. The growth hormone–IGF-I axis sends out cell-growth signs. People whose growth plates have closed would not gain from the growth push. Set against direct growth hormone, the file reads better. In-body stimulation skips the high peaks. Those peaks are tied to water hold, wrist nerve strain, and poor insulin use with outside growth hormone.

The clinical safety file is good but has edges. Work past 16 weeks is short. Rare side events may not show in the small groups so far. That line shapes how rules treat the compound today. That is the last section.

• transient facial flushing (clinical)
• injection site pain or irritation (clinical)
• transient hyperlipidemia at higher doses (clinical)

VII. Frequently Asked Questions